RxDoctor Payments Data

Kerry Krings

Optometrist · Columbus, NENPI 1730137027

Payments from drug & device makers

$1,489in general payments, 2019–2025

Across 52 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$781
  • AbbVie$281
  • Rxsight Inc$98
  • Biotissue Holdings Inc.$87
  • Coopervision Inc.$71
  • Sun Pharmaceutical Industries Inc.$55
  • plus $117 from 7 others

What the payments were for

  • Speaking & faculty fees$50034%
  • Food & beverage$98966%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,489 in reported general payments places this provider in the 75th percentile of 383 optometrist providers in Nebraska.

See all optometrist providers in Nebraska

Medicare billing

Part B allowed, 2024
$123,705
Medicare patients
741
Services billed
1,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$27,332
Cyclosporine23$10,210
VyzultaLatanoprostene Bunod17$6,072
RocklatanNetarsudil Mesylat/Latanoprost11$3,492
Travoprost11$2,455
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,314
Latanoprost123$968
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$550
Prednisolone Acetate16$485
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$460
Timolol Maleate45$349
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$229
Brimonidine Tartrate23$173
Ciprofloxacin Hcl11$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$281$27,33233 claims
Bausch & Lomb Americas Inc.Vyzulta$14$6,07217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 383 optometrist providers in Nebraska.

Other optometrist in Columbus

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →